The global subdermal contraceptive implants market size is expected to reach USD 1,245.79 million by 2032, expected to grow at a CAGR of 4.3% during the forecast period.
The subdermal contraceptive implants market is a growing segment of the global contraceptive market, driven by the increasing adoption of long-acting reversible contraceptives (LARCs). Subdermal implants, which are small, flexible rods inserted under the skin of the upper arm, provide effective contraception by releasing hormones to prevent pregnancy.
Research Scope
The research in the subdermal contraceptive implants market encompasses several areas, including:
- Development of Hormonal Combinations
- Exploring new combinations of hormones to enhance contraceptive efficacy and reduce side effects.
- Reduction of Side Effects
- Focus on minimizing side effects such as irregular bleeding or hormonal imbalances associated with implants.
- Cultural Acceptance
- Addressing cultural and religious concerns about contraceptive use through education and community engagement.
Download Free Sample PDF Copy of the Report:
The main market companies in the subdermal contraceptives industry include:
- Allergan plc
- Bayer AGKESSEL meantime GmbH
- Karex Industries.
- Mayer Laboratories
- Merck & Co., Inc.
- Nexplanon
- Reckitt Benckiser Group plc
Challenges in the Market
- High Initial Costs
- The upfront cost of subdermal implants can be a barrier for adoption, particularly in low-income regions.
- Limited Access in Rural Areas
- Poor healthcare infrastructure and limited availability of trained professionals hinder market growth in remote areas.
- Cultural and Religious Barriers
- Resistance to contraceptive use due to cultural and religious beliefs remains a challenge in certain regions.
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:
The research report categorizes the market into various segments and sub-segments. The primary segments covered in the study include type, application, end use and region. The splitting of the market into various groups enables businesses to understand market preferences and trends better. Also, stakeholders can develop products/services that align with the diverse needs of consumers in the industry. Besides, the research study includes a thorough examination of all the major sub-segments in the market.
Subdermal Contraceptive Implants, Product Outlook (Revenue – USD Million, 2019 – 2032)
- Levonorgestrel Implant
- Etonogestrel Implant
Subdermal Contraceptive Implants, Implant Outlook (Revenue – USD Million, 2019 – 2032)
- single rod
- Two-rod
Subdermal Contraceptive Implants, End-Use Outlook (Revenue – USD Million, 2019 – 2032)
- Hospitals
- Clinics
- Others
Recent Developments
- In April 2022, ProMed Pharma commenced a preclinical assessment of an innovative, fully resorbable contraceptive implant. This development was made possible by receiving Bill & Melinda Gates Foundation funding.
The subdermal contraceptive implants market is witnessing significant growth, driven by increasing demand for long-acting contraceptives, supportive policies, and advancements in implant technology. While challenges such as high costs and cultural resistance persist, the market’s potential remains immense, especially in underserved regions. Continued investment in education, innovation, and accessibility will play a crucial role in shaping the future of this market.